Dr. Allan Pantuck is the Chairman, co-Founder, and Chief Medical Officer of Athos Therapeutics Inc. He was a co-founder of Kite Pharma, a biotech company that successfully developed and obtained FDA approval for an innovative cancer immunotherapy and was acquired from Gilead Sciences in 2017. He is currently a Professor of Urology at UCLA David Geffen School of Medicine, Executive Chair of the UCLA IRB Committee, Vice Chair of Academic Affairs for the Department of Urology and a member of the Executive Committee of the Institute of Urologic Oncology. He performed his urology/oncology fellowship and was awarded a Masters of Clinical Research from UCLA School of Medicine, and holds an MD degree from Robert Wood Johnson/Rutgers Medical School. Dr Pantuck is also on the scientific and advisory boards of several biotechnology and pharmaceutical companies, In addition to authoring several pending US patent applications, Dr. Pantuck has lectured internationally, written over 300 peer-reviewed biomedical publications, he is a scientific and advisory consultant to big pharma companies providing his expertise on regulatory strategy and clinical trial design.
